- Home
- RLAY vs SBFM Comparison
RLAY vs SBFM Comparison
Compare RLAY & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- SBFM
- Stock Information
- Founded
- RLAY 2015
- SBFM 2006
- Country
- RLAY United States
- SBFM United States
- Employees
- RLAY N/A
- SBFM N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- RLAY Health Care
- SBFM Health Care
- Exchange
- RLAY Nasdaq
- SBFM Nasdaq
- Market Cap
- RLAY 576.1M
- SBFM 7.7M
- IPO Year
- RLAY 2020
- SBFM N/A
- Fundamental
- Price
- RLAY $3.63
- SBFM $1.54
- Analyst Decision
- RLAY Strong Buy
- SBFM Strong Buy
- Analyst Count
- RLAY 11
- SBFM 1
- Target Price
- RLAY $18.40
- SBFM $15.00
- AVG Volume (30 Days)
- RLAY 1.6M
- SBFM 183.8K
- Earning Date
- RLAY 08-05-2025
- SBFM 08-15-2025
- Dividend Yield
- RLAY N/A
- SBFM N/A
- EPS Growth
- RLAY N/A
- SBFM N/A
- EPS
- RLAY N/A
- SBFM N/A
- Revenue
- RLAY $7,679,000.00
- SBFM $36,234,578.00
- Revenue This Year
- RLAY $14.31
- SBFM $192.48
- Revenue Next Year
- RLAY N/A
- SBFM N/A
- P/E Ratio
- RLAY N/A
- SBFM N/A
- Revenue Growth
- RLAY N/A
- SBFM 35.51
- 52 Week Low
- RLAY $1.78
- SBFM $1.17
- 52 Week High
- RLAY $10.72
- SBFM $7.60
- Technical
- Relative Strength Index (RSI)
- RLAY 63.22
- SBFM 53.29
- Support Level
- RLAY $3.10
- SBFM $1.42
- Resistance Level
- RLAY $3.75
- SBFM $1.75
- Average True Range (ATR)
- RLAY 0.23
- SBFM 0.12
- MACD
- RLAY 0.03
- SBFM 0.01
- Stochastic Oscillator
- RLAY 84.42
- SBFM 44.44
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.